How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Combined Heart Device Market
- By Device Type: Implantable Cardioverter Defibrillators (ICDs), Cardiac Resynchronization Therapy Devices (CRT-D and CRT-P), Pacemakers (Single Chamber, Dual Chamber, Biventricular), Wearable Cardiac Devices
- By Therapy Application: Arrhythmia Management, Heart Failure Management, Bradycardia Treatment, Tachycardia Treatment
- By Device Technology: MRI-Compatible Devices, Leadless Pacemakers, Subcutaneous ICDs, Transvenous ICDs
- By Battery Type: Lithium-Ion Batteries, Lithium Silver Vanadium Oxide Batteries, Rechargeable Batteries
- By Patient Demographics: Adult Patients, Pediatric Patients, Geriatric Patients
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Implantable Cardioverter Defibrillators (ICDs) leads By Device Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the Combined Heart Device Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Device Type 4
Therapy Application 4
Device Technology 4
Battery Type 3
Patient Demographics 3
Companies profiled
Medtronic
Abbott Laboratories
Boston Scientific
Edwards Lifesciences
Biotronik
LivaNova
Abiomed
Sorin Group (now part of LivaNova)
Getinge (Maquet)
Terumo Corporation
MicroPort Scientific Corporation
CardiacAssist Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Boston Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Edwards Lifesciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Biotronik
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →LivaNova
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Abiomed
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sorin Group (now part of LivaNova)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Getinge (Maquet)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Terumo Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →MicroPort Scientific Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →CardiacAssist Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →SynCardia Systems
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Carmat
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Nipro Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,351M by 2033 · 10.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Implantable Cardioverter Defibrillators (ICDs)64.1
- Cardiac Resynchronization Therapy Devices (CRT-D and CRT-P)8.5
- Pacemakers (Single Chamber, Dual Chamber, Biventricular)17.6
- Wearable Cardiac Devices9.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,433M → $3,290M · 10.9%
Europe$998.7M → $2,023M · 9.2%
Asia Pacific$911.8M → $1,912M · 9.7%
Latin America$564.5M → $1,332M · 11.3%
Middle East and Africa$434.2M → $980.9M · 10.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.022026
10.022027
10.042028
10.052029
10.072030
10.072031
10.092032
10.102033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic20.9
- Abbott Laboratories14.9
- Boston Scientific5.2
- Edwards Lifesciences14.2
- Biotronik11.5
- LivaNova5.2
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Device Type12.0%
Therapy Application20.3%
Device Technology22.1%
Battery Type11.6%
Patient Demographics33.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.5
- Europe21.2
- Asia Pacific20.0
- Latin America14.0
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic | 86 | 83 | 91 | 78 | 78 | 78 | 82 |
| Abbott Laboratories | 80 | 90 | 93 | 72 | 92 | 85 | 85 |
| Boston Scientific | 77 | 73 | 70 | 75 | 70 | 63 | 71 |
| Edwards Lifesciences | 75 | 71 | 70 | 75 | 71 | 63 | 71 |
| Biotronik | 74 | 58 | 63 | 77 | 56 | 74 | 67 |
| LivaNova | 57 | 54 | 69 | 54 | 50 | 47 | 55 |
| Abiomed | 54 | 59 | 56 | 64 | 48 | 47 | 55 |
| Sorin Group (now part of LivaNova) | 42 | 36 | 57 | 46 | 37 | 57 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic
- Abbott Laboratories
- Boston Scientific
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic | ◐ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Abbott Laboratories | ◐ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Boston Scientific | ◐ | − | ◐ | ✓ | − | ◐ |
| Edwards Lifesciences | ◐ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Biotronik | ✓ | − | − | ◐ | ◐ | ◐ |
| LivaNova | ◐ | ◐ | ◐ | − | − | − |
| Abiomed | ◐ | ◐ | − | − | − | ◐ |
| Sorin Group (now part of LivaNova) | − | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories85
2Medtronic82
3Boston Scientific71
4Edwards Lifesciences71
5Biotronik67
6LivaNova55
7Abiomed55
8Sorin Group (now part of LivaNova)46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
MedtronicAbbott Laboratories
Challenger3
Strong scale, closing on the leaders.
Boston ScientificEdwards LifesciencesBiotronik
Niche3
Specialists in a single segment or region.
LivaNovaAbiomedSorin Group (now part of LivaNova)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Device Type in North America, then scale across Combined Heart Device Market — a $568M beachhead inside a $10.5B market.
Beachhead (SOM)$568Mobtainable near-term
Serviceable (SAM)$3.79Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Implantable Cardioverter Defibrillators (ICDs)
Best fit — highest urgency & budget in Device Type.
Economic buyer76 fit
Cardiac Resynchronization Therapy Devices (CRT-D and CRT-P)
Strong fit — clear ROI and a fast path to value.
End user67 fit
Pacemakers (Single Chamber, Dual Chamber, Biventricular)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Device Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapy Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Device Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel26%
Digital / self-serve21%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Device Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Combined Heart Device Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified22%
Evaluation12%
Closed-won8%
$15.7KCAC
$61KLTV
3.9:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Combined Heart Device Market is a resilient opportunity — $5.82B by 2033, compounding at 4.5%.
TAM · 2025$4.10Btoday
TAM · 2033$5.82Bforecast
CAGR4.5%2027–2033
Cumulative$44.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.82BTotal addressable market
SAM$2.10BServiceable available market
SOM$433MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.5% CAGR
Demand compounds through 2033, outpacing GDP across Device Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Device Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.82BLarge & growingTAM by 2033 at 4.5% CAGR
$2.10BServiceable nowreachable with today’s model
$433MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.54BBear2.9% CAGR
$5.82BBase4.5% CAGR
$7.45BBull5.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapy Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Combined Heart Device Market — a $3.03B market by 2033. Plan: grow share from 9.1% to 14.0%.
Market size · 2033$3.03Btotal addressable
Market CAGR10.1%2027–2033
Target share14.0%from 9.1% today
Revenue ambition$424Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 14.0% | On track |
| Revenue | $251M | $424M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 36.0% | 43.6% | On track |
| Customer retention | 86.5% | 92.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Device Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapy Application capability
A defensible second engine — invest in Therapy Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Device Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapy Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $56M capacity & capability investment
- Greenlight bolt-on M&A in Therapy Application
- Authorise North America expansion plan
- Fund R&D program for Device Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Combined Heart Device Market conversation — a $4.35B market you can size, segment and defend in minutes.
Market size · 2033$4.35Btotal opportunity
Growth11.6%CAGR to 2033
Addressable buyers1,337+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Device Type
Goal Grow share in Device Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 4 mopayback period
$98K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
MedtronicAbbott LaboratoriesBoston ScientificEdwards LifesciencesBiotronikLivaNovaAbiomedSorin Group (now part of LivaNova)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Combined Heart Device Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Combined Heart Device Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Combined Heat & Power (CHP) Systems Market
Market size, share, segmentation and regional forecast.
$404M market · 2025 base year
View reportCombined Heat & Power Installation Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportCombined Heat And Power For Commercial Buildings Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportCombined Slide Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportCombined Track Harvester Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportCombined Transformer For Photovoltaic Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportCombined Vaccine Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportCombined Wheel Harvester Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportCombiner Box Spd State Acquisition Device Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportCombo-Chip For Tablet Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportCombustible Gas Alarm Control Units Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportCombustible Gas Alarm Controller Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.